{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024446","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.556847+00:00","generated_at":"2026-06-21T23:06:02.071585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance","bullets":["Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.","Cash $290.4M at Sept 30, up from $208.4M at Dec 31, 2021, driven by ATM proceeds.","MISSION Phase 2 lupus nephritis: ORR 64.7% at week 25, 88.2% at week 37; CRR 35.3% then 41.2%.","FDA cleared IND for zetomipzomib in autoimmune hepatitis; PORTOLA Phase 2a trial to start.","Preclinical KZR-540, an oral PD-1 expression blocker, presented at SITC on Nov 11."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024446","json":"https://secwatch.observer/filing/0000950170-22-024446.json","markdown":"https://secwatch.observer/filing/0000950170-22-024446.md","text":"https://secwatch.observer/filing/0000950170-22-024446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/0000950170-22-024446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/kzr-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:06:02.071585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f63181ac844d8d82469b03d0496ab354b3e8c519","claim":"Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Kezar Life Sciences Reports Third Quarter 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/0000950170-22-024446-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}